Biotechnology News and Research RSS Feed - Biotechnology News and Research

Oysters play important role in persistence and transmission of norovirus

Oysters play important role in persistence and transmission of norovirus

Oysters not only transmit human norovirus; they also serve as a major reservoir for these pathogens, according to research published August 28 in Applied and Environmental Microbiology, a journal of the American Society for Microbiology. "More than 80 percent of human norovirus genotypes were detected in oyster samples or oyster-related outbreaks," said corresponding author Yongjie Wang, PhD. [More]
Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs. [More]
Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to improve survival. St. Jude Children's Research Hospital scientists led the study, which was published online today in the journal Cancer Cell. [More]
Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP). [More]
Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario. [More]
Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London. [More]
BD Life Sciences completes acquisition of Cellular Research

BD Life Sciences completes acquisition of Cellular Research

BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company), today announced it has completed the acquisition of Cellular Research, Inc. [More]
HCMC Co-Founder Derek Muhs to present keynote speech at HOSCON Summit in New Delhi, India

HCMC Co-Founder Derek Muhs to present keynote speech at HOSCON Summit in New Delhi, India

Health Care Management China today announced that Co-Founder and Vice Chairman Derek Muhs will present a keynote speech at the 6th annual Hospital Construction (HOSCON) Summit in New Delhi, India from September 3-4, 2015. [More]
Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

In response to the growing opioid crisis, several states, including Massachusetts and Rhode Island, have granted pharmacists the authority to provide naloxone rescue kits without a prescription to at-risk patients. This model of pharmacy-based naloxone (PBN) education and distribution is one of the public health strategies currently being evaluated at hundreds of pharmacies in both states to determine the impact on opioid overdose death rates. [More]
Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015. [More]
Accutest makes strategic expansion into Latin America to support the growth of pharmaceutical sector

Accutest makes strategic expansion into Latin America to support the growth of pharmaceutical sector

Accutest Research Laboratories, a leading global Contract Research Organization (CRO), further pursues its strategic expansion into Latin America by opening offices and establishing operational presence in Brazil. [More]
Regen BioPharma implements gene silencing technology in killing cancer stem cells

Regen BioPharma implements gene silencing technology in killing cancer stem cells

Regen BioPharma Inc. reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. [More]
Benitec Biopharma announces closing of U.S. initial public offering of ADSs

Benitec Biopharma announces closing of U.S. initial public offering of ADSs

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares. [More]
New ASU-POSTECH collaboration aims to discover biological molecules for health care, renewable energy research

New ASU-POSTECH collaboration aims to discover biological molecules for health care, renewable energy research

The Biodesign Institute at Arizona State University and Pohang University of Science and Technology (POSTECH), Pohang, South Korea, have announced a partnership that will catalyze discoveries with a major impact on health care and clean energy applications. [More]
Stanford University launches new professional education course

Stanford University launches new professional education course

Imagine a world where health care is personalized, diseases are treated or even prevented before they become debilitating, and doctor's visits include regular reviews of individual genetic profiles. These are just some of the possibilities at the intersection of healthcare and genomics. [More]
Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg, a Boston-based biopharmaceutical company, and the University of Miami Leonard M. Miller School of Medicine are extending its collaboration to battle cardiac dysfunction and heart failure. According to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030. [More]
NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol. [More]
MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma. [More]
NYBC, UC Davis Health System partner to manufacture potential stem cell therapies

NYBC, UC Davis Health System partner to manufacture potential stem cell therapies

New York Blood Center today announced a new collaboration with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for repair and regeneration of retina, kidney, lung and liver tissue, as well as for the treatment of neurodegenerative disorders such as Parkinson's, Alzheimer's and Huntington's disease. [More]
Scientists develop technique to rejuvenate cells from older osteoarthritis patients

Scientists develop technique to rejuvenate cells from older osteoarthritis patients

A research team at York has adapted the astonishing capacity of animals such as newts to regenerate lost tissues and organs caused when they have a limb severed. [More]
Advertisement
Advertisement